# Ivermectin in Cancer: a checklist for patients ## Ivermectin in Cancer: a checklist for patients ### In this section * [Ivermectin in cancer: a simple checklist for a more informed look](#ivermectin-in-cancer-a-simple-checklist-for-a-more-informed-look) * [A T-cell subset can help you think about where you sit](#a-t-cell-subset-can-help-you-think-about-where-you-sit) * [So the real boxes to tick are not just “am I taking ivermectin?” but](#so-the-real-boxes-to-tick-are-not-just-am-i-taking-ivermectin-but) * [Direct tumour-cell targets seen in preclinical work](#direct-tumour-cell-targets-seen-in-preclinical-work) * [If you are considering ivermectin for pathway-targeting reasons, ask](#if-you-are-considering-ivermectin-for-pathway-targeting-reasons-ask) * [Another thing to think about: how long should it take to see something?](#another-thing-to-think-about-how-long-should-it-take-to-see-something) * [Final thought](#final-thought) * [Studies and reviews mentioned](#studies-and-reviews-mentioned) ### Ivermectin in cancer: a simple checklist for a more informed look I have been reading more about how ivermectin might interact with tumours and why it may be failing to work as well as many hope. As everyone here knows, cancer itself, plus cancer treatment, often leaves the immune system compromised. If you want a clearer picture of whether ivermectin’s immune-based effects even have a chance to work, you can ask your doctor to order a T-cell subset blood test — or in some places order one yourself and have someone knowledgeable help you interpret it. A T-cell subset test gives you more useful detail than a standard white blood cell count because it shows your CD4 and CD8 T-cell numbers directly. When the immune system is damaged by treatment or simply out of shape after years of fighting cancer, adding ivermectin at any dose does not necessarily help it kill cancer cells through immunogenic cell death. That pathway still needs a functioning immune response team — especially CD8 T cells, dendritic cells, and helpful macrophages — to respond to the alarm signals coming from the tumour. ### A T-cell subset can help you think about where you sit * **Near-normal:** CD4 and CD8 are within or close to range. The responsive immune cells we need are present. * **Moderately suppressed:** CD4 and/or CD8 are below range, but not profoundly low. The responsive immune cells we need are under-staffed, so immune-dependent benefit may be weaker. This is where I personally sit, and where many people in this group seem to sit too. * **Profoundly suppressed:** CD4 and/or CD8 are very low. The responsive immune cells we need are missing, and raising the dose of ivermectin will not rebuild CD4 and/or CD8 cells. ### Important limitations of reading this from blood counts A T-cell subset can still be useful. It is not the whole picture. This is peripheral blood, not the tumour microenvironment. It cannot show: * how many T cells are actually inside the tumour * whether tumour-associated macrophages are more M1-like or M2-like * whether myeloid-derived suppressor cells are blocking responses * whether dendritic cells are presenting antigen effectively The numbers also do not show T-cell quality. They cannot tell you: * how exhausted those T cells are after years of disease and treatment * how well they proliferate, produce cytokines, and kill target cells They also do not account well for recent treatment effects. Chemotherapy, steroids, CDK4/6 inhibitors, and other treatments can temporarily push these counts around. So this kind of testing is best used as a rough read on immune hardware, not as a full immune map. It can help you judge whether some response capacity may still be present, or whether response capacity looks severely depleted. It does not make ivermectin a proven treatment or that it has no possible role. In laboratory studies, it has also been shown to damage cancer-cell mitochondria, increase oxidative stress, and interfere with signalling pathways some tumours rely on. So if a cancer depends on pathways that ivermectin happens to hit, there may still be a more direct, non-immune reason to consider it. But this is the key question: are you using ivermectin because it matches something real in your cancer biology, or because you are hoping more dose will make up for a weak immune system? More ivermectin does not create more CD8 T cells, dendritic cells, or M1 macrophages. And at higher exposures, there is also preclinical evidence that it may stress macrophages themselves, which could make things harder for an already struggling immune system. ### So the real boxes to tick are not just “am I taking ivermectin?” but: * Do I at least know my CD4 and CD8 counts from a T-cell subset? * Is my immune response team still present in reasonable numbers? * Am I using ivermectin to target pathways relevant to my cancer? * Am I expecting it to support an existing immune response, or to replace one that is already depleted? * Am I assuming higher dose means better effect, without evidence that it improves the part I actually need? At this stage, most of the positive evidence still comes from cell and animal studies. So while ivermectin clearly has interesting anticancer mechanisms in preclinical work, it is still not clear how safely or effectively those effects translate into real people, especially at very high doses. ### Direct tumour-cell targets seen in preclinical work Even when immune support is weak, ivermectin may still have direct tumour-cell effects in preclinical models, but these are context-dependent and not clinically validated across cancers. In most of these cell-line studies, cancer cells are exposed to micromolar concentrations of ivermectin. At those levels, researchers see strong oxidative stress: ROS levels rise, mitochondrial membrane potential collapses, ATP drops, and apoptosis is triggered through the mitochondrial pathway. Normal cells in the same dishes usually cope better at lower micromolar doses, but they also begin to show toxicity as the concentration climbs. That suggests there may be some selectivity, but not a magic shield. And this matters: standard oral doses in humans produce blood levels well below the concentrations used in many of these cell-line experiments. There is no real-world evidence on what repeated dosing high enough to try to mimic those exposures in tumours would do to healthy mitochondria-dependent tissues like the brain, nerves, heart, liver, and immune cells. So another question to ask is this: if high-dose ivermectin is being used to chase a mitochondrial or ROS effect, do we really know where the benefit ends and healthy-cell stress begins? ### If you are considering ivermectin for pathway-targeting reasons, ask: **Have I, or my team, identified any of these as likely drivers in my cancer — through tumour testing, blood work, or by reading research on my cancer type?** * Wnt / beta-catenin / integrin beta1 / FAK * Akt / mTOR and mitochondrial stress pathways * EGFR / ERK / Akt / NF-kappaB * STAT3 * P2X4 / P2X7 purinergic signalling * PAK1 * FOXA1 and Ku70 / Ku80 * ER, HER2, and TGF-beta signalling **Are any of these already being targeted by other drugs, supplements, or parts of my protocol?** Am I using ivermectin because it is hitting something seen in my cancer biology, or because I am simply hoping it will work broadly? Am I assuming that because high-dose ivermectin can damage mitochondria in cancer cells, more will necessarily be better in the body? ### Another thing to think about: how long should it take to see something? This is a question I do not think enough people ask. If ivermectin is being used at high dose because of animal work or cell-line theory, then do we actually know how long it should take to see some meaningful tumour response? Do we know what degree of tumour shrinkage was seen in the animal studies, and after how many days or weeks? And if someone has been pushing high-dose ivermectin for a long time without any sign of slowed growth or shrinkage, are they still treating cancer — or are they simply creating stress and damage in a vulnerable body without knowing it? The animal studies are short, controlled experiments. They do not tell us that indefinite high-dose use in humans is safe. And they do not tell us that “keep going and keep pushing the dose” is evidence-based either. That is one of the biggest blind spots here. If the hoped-for benefit is meant to come from mitochondrial stress, ROS, immune signalling, or tumour-pathway inhibition, then at some point it is reasonable to ask: * How long should it take before I expect to see some effect? * What did the animal studies actually show, and over what timeframe? * Am I still within a rational trial of something, or am I now in an open-ended experiment on my own vulnerable body? * If I have seen no sign of response, do I actually know whether I am still helping myself — or just adding more metabolic, neurological, hepatic, or immune stress? I think these are fair questions, especially when the same pathways ivermectin may stress in tumour cells also exist in the healthy cells we need to pull us through. ### Final thought This is not written as someone claiming to have all the answers. It is written as someone trying to ask better questions. I am asking them because I too have been exploring this off-label drug in my own protocol, and the deeper I go into the research, the more I realise how much there is that I may not have fully considered — especially around immune readiness, pathway relevance, dosing assumptions, and the possibility of healthy-cell stress when chasing anticancer effects seen mainly in lab models.
#### Want to Share this information? Share this:\ **Ivermectin & Cancer Checklist**. It’s not pro‑ or anti‑iver. Instead, it walks you through the *questions* most of us were never told to ask: [**www.myhealingcommunity.com/iver-cancer-checklist**](https://www.myhealingcommunity.com/iver-cancer-checklist) ### Studies and reviews mentioned * [Ivermectin, a potential anticancer drug derived from an antiparasitic drug (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/) * [Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (2021)](https://www.nature.com/articles/s41523-021-00229-5) * [Immunotoxicity induced by Ivermectin is associated with NF-kappaB signaling pathway on macrophages (2022)](https://pubmed.ncbi.nlm.nih.gov/34843829/) * [Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects (2002)](https://pubmed.ncbi.nlm.nih.gov/12362927/) * [Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641399/) * [Integrated analysis reveals FOXA1 and Ku70 / Ku80 as targets of ivermectin in prostate cancer (2022)](https://pubmed.ncbi.nlm.nih.gov/36050295/) * [Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells (2026)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0348260) * [The multitargeted drug ivermectin: from an antiparasitic agent to a promising anticancer drug (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5835698/) * [Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in esophageal squamous cell carcinoma (2020)](https://onlinelibrary.wiley.com/doi/10.1111/jcmm.15195)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/ivermectin-in-cancer-a-checklist-for-patients.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.